169 related articles for article (PubMed ID: 30899435)
1. Correction: Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls.
Le Gall G; Guttula K; Kellingray L; Tett AJ; Hoopen RT; Kemsley EK; Savva GM; Ibrahim A; Narbad A
Oncotarget; 2019 Feb; 10(17):1660. PubMed ID: 30899435
[TBL] [Abstract][Full Text] [Related]
2. Correction: Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer.
Jiang H; Tang E; Xu D; Chen Y; Zhang Y; Tang M; Xiao Y; Zhang Z; Deng X; Li H; Lin M
Oncotarget; 2018 Oct; 9(82):35373. PubMed ID: 30450164
[TBL] [Abstract][Full Text] [Related]
3. Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.
Nivarthi H; Gordziel C; Themanns M; Kramer N; Eberl M; Rabe B; Schlederer M; Rose-John S; Knösel T; Kenner L; Freund P; Aberger F; Han X; Kralovics R; Dolznig H; Jennek S; Friedrich K; Moriggl R
Oncotarget; 2018 Sep; 9(73):33865. PubMed ID: 30333916
[TBL] [Abstract][Full Text] [Related]
4. Correction: Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression.
Lu W; Wang J; Yang G; Yu N; Huang Z; Xu H; Li J; Qiu J; Zeng X; Chen S; Li N; Liu H
Oncotarget; 2018 Feb; 9(15):12535. PubMed ID: 29552332
[TBL] [Abstract][Full Text] [Related]
5. Correction: Genipin suppresses colorectal cancer cells by inhibiting the Sonic Hedgehog pathway.
Kim BR; Jeong YA; Na YJ; Park SH; Jo MJ; Kim JL; Jeong S; Lee SY; Kim HJ; Oh SC; Lee DH
Oncotarget; 2018 Jun; 9(47):28796. PubMed ID: 29983897
[TBL] [Abstract][Full Text] [Related]
6. Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
Ahmed MA; Selzer E; Dörr W; Jomrich G; Harpain F; Silberhumer GR; Müllauer L; Holzmann K; Grasl-Kraupp B; Grusch M; Berger W; Marian B
Oncotarget; 2019 Sep; 10(51):5385-5386. PubMed ID: 31555396
[TBL] [Abstract][Full Text] [Related]
7. Correction: A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin.
Geagea AG; Rizzo M; Jurjus A; Cappello F; Leone A; Tomasello G; Gracia C; Kattar SA; Massaad-Massade L; Eid A
Oncotarget; 2019 Nov; 10(60):6538-6539. PubMed ID: 31741717
[TBL] [Abstract][Full Text] [Related]
8. Correction: Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer.
Zhang X; Ma X; An H; Xu C; Cao W; Yuan W; Ma J
Oncotarget; 2020 Jan; 11(1):115. PubMed ID: 32002128
[TBL] [Abstract][Full Text] [Related]
9. Correction: New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.
Telechea-Fernández M; Rodríguez-Fernández L; García C; Zaragozá R; Viña JR; Cervantes A; García-Trevijano ER
Oncotarget; 2018 Apr; 9(26):18664. PubMed ID: 29722369
[TBL] [Abstract][Full Text] [Related]
10. Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.
Chocry M; Leloup L; Kovacic H
Oncotarget; 2018 Jun; 9(42):26978-26979. PubMed ID: 29928496
[TBL] [Abstract][Full Text] [Related]
11. Correction: Compliance with the enhanced recovery after surgery protocol and prognosis after colorectal cancer surgery: A prospective cohort study.
Li L; Jin J; Min S; Liu D; Liu L
Oncotarget; 2017 Oct; 8(52):90605. PubMed ID: 29163855
[TBL] [Abstract][Full Text] [Related]
12. Correction: LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics.
Yao Q; An Y; Hou W; Cao YN; Yao MF; Ma NN; Hou L; Zhang H; Liu HJ; Zhang B
Oncotarget; 2020 Aug; 11(32):3102. PubMed ID: 32850013
[TBL] [Abstract][Full Text] [Related]
13. Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using
Weiss ID; Huff LM; Evbuomwan MO; Xu X; Dang HD; Velez DS; Singh SP; Zhang HH; Gardina PJ; Lee JH; Lindenberg L; Myers TG; Paik CH; Schrump DS; Pittaluga S; Choyke PL; Fojo T; Farber JM
Oncotarget; 2018 Oct; 9(77):34641. PubMed ID: 30349656
[TBL] [Abstract][Full Text] [Related]
14. Correction: Interaction between physical activity,
Gunathilake MN; Lee J; Cho YA; Oh JH; Chang HJ; Sohn DK; Shin A; Kim J
Oncotarget; 2018 Oct; 9(79):35027. PubMed ID: 30405892
[TBL] [Abstract][Full Text] [Related]
15. Correction: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.
Zhang J; He P; Xi Y; Geng M; Chen Y; Ding J
Oncotarget; 2020 Jan; 11(3):302-303. PubMed ID: 32076491
[TBL] [Abstract][Full Text] [Related]
16. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
17. Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.
Hu Y; Yu T; Liu X; He Y; Deng L; Guo J; Hua Y; Luo T; Gao X
Oncotarget; 2020 Sep; 11(37):3484-3485. PubMed ID: 32973972
[TBL] [Abstract][Full Text] [Related]
18. Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
Satake H; Sunakawa Y; Miyamoto Y; Nakamura M; Nakayama H; Shiozawa M; Makiyama A; Kobayashi K; Kubota Y; Mori M; Kotaka M; Takagane A; Gotoh M; Takeuchi M; Fujii M; Ichikawa W; Sekikawa T
Oncotarget; 2018 Jul; 9(52):30023. PubMed ID: 30042830
[TBL] [Abstract][Full Text] [Related]
19. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
Evans JP; Winiarski BK; Sutton PA; Jones RP; Ressel L; Duckworth CA; Pritchard DM; Lin ZX; Fretwell VL; Tweedle EM; Costello E; Goldring CE; Copple IM; Park BK; Palmer DH; Kitteringham NR
Oncotarget; 2019 Jan; 10(6):685. PubMed ID: 30774766
[TBL] [Abstract][Full Text] [Related]
20. Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.
Carter P; Alifrangis C; Chandrasinghe P; Cereser B; Del Bel Belluz L; Leo CA; Moderau N; Tabassum N; Warusavitarne J; Krell J; Stebbing J
Oncotarget; 2018 Mar; 9(19):15165. PubMed ID: 29601069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
